461 Studies Now Enrolling
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDYEVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Study of PF-07263689 Alone or in Combination with Sasanlimab for Patients with Advanced Cancer
| Sponsor: | Pfizer |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAT8070 |
| U.S. Govt. ID: | NCT05061537 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to learn about the safety and anti-cancer effectiveness of the investigational study drug called PF-07263689, as a single agent and in combination with sasanlimab, another investigational study drug that is an anti-PD 1 antibody. PF 07263689 is a weakened, live virus form of the pox-type virus (related to smallpox) and has been genetically modified to try to help your immune system to kill tumor cells. Sasanlimab is an antibody against a protein called PD-1 that is located on your immune cells and may help prevent PD-1 from interacting with another protein, PD-L1, located on the surface of tumors. Blocking this interaction may help improve the immune response against cancer cells. Cancers include bladder cancer, breast cancer, colon and rectal cancer, ovarian cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer, and prostate cancer.
This study is closed
Do You Qualify?
| Are you at least 18 years old? | Yes | No |
| Have you exhausted all available standard of care therapy or have no standard of care therapy available for your tumor type? | Yes | No |
| Are you willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures? | Yes | No |
| Do you have any prior or planned organ transplants? | Yes | No |